Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 13, 2020

Fujifilm evaluates Avigan to treat Covid-19 in US

Japanese company Fujifilm has launched a Phase II clinical trial of its influenza drug Avigan (favipiravir) to treat Covid-19 patients in the US.

Japanese company Fujifilm has launched a Phase II clinical trial of its influenza drug Avigan (favipiravir) to treat Covid-19 patients in the US.

Approved in 2014 in Japan, Avigan specifically targets RNA polymerase required for influenza virus replication.

This mechanism is also expected to have an antiviral effect on the novel coronavirus, which is a single-stranded RNA virus similar to influenza and requires viral RNA polymerase.

For the new study in the US,  around 50 coronavirus patients will be enrolled at Brigham and Women’s Hospital, Massachusetts General Hospital and the University of Massachusetts Medical School.

The trial will evaluate the drug’s safety and efficacy as a potential Covid-19 therapy.

Apart from treatment studies for Covid-19, the company is working to boost the production of Avigan to help fight the pandemic.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

In a statement, Fujifilm said: “Fujifilm will continue to work to establish a treatment method for Covid-19 patients through conducting clinical trials, and to contribute to ending the spread of this global pandemic as soon as possible by increasing the production of Avigan in collaboration with strategic partners.”

Avigan is intended for use during new or re-emerging influenza virus outbreaks when other treatments are not adequately effective.

It is produced and distributed upon request by the government of Japan, which has a stockpile of the drug. Avigan was never distributed in the market and is not available at hospitals and pharmacies in Japan or internationally.

Earlier this month, Fujifilm commenced a Phase III trial of Avigan for the treatment of Covid-19 patients in Japan.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU